WASHINGTON, D.C. - The National Institute of Health (NIH) has received approval from the U.S. Food and Drug Administration (FDA) to begin human testing of a new Ebola vaccine. This will be welcome news for the millions of Americans who now face the very real possibility of encountering someone with the disease or contracting it themselves.
Currently, 357 people are being monitored in New York for possible exposure to the deadly virus, and Texas which was the epicenter for the first mortality from Ebola in the U.S. has been declared Ebola free.
According to the Los Angeles Times, "Nine people have been treated in the U.S. for Ebola, including Thomas Eric Duncan, a Liberian who died last month. One doctor, Craig Spencer, remains hospitalized in stable condition in New York."
The vaccine is undergoing a "human safety trial," which means it will be tested on "healthy human subjects to evaluate the immune response, identify any side effects and determine the appropriate dosage." (Source: NewLink Genetics)
The vaccine was developed by the pharmaceutical company Glaxosmithkline and the National Institute of Allergy and Infectious Diseases (NIAID), and is one of several being developed worldwide.
Earlier in the outbreak, the drug Zmapp was administered to seven aid workers. Five of the workers survived, though it's unclear how large a role the drug played in their survival. Due to the emergency status of the outbreak, treatments are not being monitored and tested as thoroughly as they would be if there was more time. Nevertheless, the U.S. Department of Health and Human Services has granted an $24.9 million 18-month contract with the manufacturer of Zmapp to expedite the development process.
VSV-EBOV is another experimental vaccine for the Ebola filovirus, developed by scientists at the Canadian National Microbiology Laboratory and is currently being tested in clinical trials in the U.S. at the Walter Reed Army Institute of Research in Silver Spring, Md. This vaccination purportedly does not induce any fever or other symptoms of illness. There is also evidence that this type of vaccine which can be administered orally or intranassaly as nose-drops may have potential as a treatment for those already infected. (Source: Wikipedia)
In Canada, permission has been granted for the vaccine VSV EBOV to be sent to Africa, but problems such as refrigeration during transport and storage have come up. Many of the villages that are most in need are in remote areas with bad roads, infrequent electricity, and and treatment is further hindered by the citizens mistrust of new technologies. It's clear that while developing a vaccine is an enormous step forward in the Ebola fight, there are still many political and practical obstacles to overcome.
- Medical Research Institute Contributes to Vaccine Development Effort (defense.gov)
- Ebola Clinical Trials: Big Name Players In The Ebola Race (biospace.com)
- Ebola vaccine abandoned in 2008 after showing promise in trials (washingtontimes.com)